Brokerages Set Humana Inc. (NYSE:HUM) PT at $281.43

Shares of Humana Inc. (NYSE:HUM) have received a consensus recommendation of “Hold” from the twenty-three ratings firms that are covering the stock, MarketBeat reports. Sixteen research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $283.2857.

Several equities analysts recently weighed in on the company. Barclays set a $275.00 price objective on Humana and gave the company an “equal weight” rating in a research note on Thursday, July 31st. Wall Street Zen cut Humana from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Cantor Fitzgerald reiterated a “neutral” rating and set a $290.00 target price on shares of Humana in a report on Thursday, May 1st. Robert W. Baird lowered their target price on Humana from $300.00 to $297.00 and set a “neutral” rating on the stock in a report on Friday, July 25th. Finally, Bank of America decreased their price objective on Humana from $320.00 to $260.00 and set a “neutral” rating on the stock in a report on Tuesday, June 17th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cary Street Partners Investment Advisory LLC boosted its holdings in Humana by 63.9% in the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock valued at $31,000 after acquiring an additional 46 shares during the last quarter. Riverview Trust Co purchased a new position in Humana in the first quarter valued at about $34,000. Elevation Point Wealth Partners LLC purchased a new position in Humana in the second quarter valued at about $32,000. Garde Capital Inc. purchased a new position in Humana in the first quarter valued at about $36,000. Finally, Zions Bancorporation National Association UT purchased a new position in Humana in the first quarter valued at about $37,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Performance

Shares of HUM stock opened at $300.0120 on Monday. The company has a market cap of $36.08 billion, a price-to-earnings ratio of 23.02, a price-to-earnings-growth ratio of 1.73 and a beta of 0.44. The stock has a 50 day simple moving average of $248.58 and a 200-day simple moving average of $253.73. Humana has a 12-month low of $206.87 and a 12-month high of $382.72. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.32 by ($0.05). The business had revenue of $32.39 billion for the quarter, compared to analysts’ expectations of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%.The business’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period last year, the company posted $6.96 earnings per share. Humana has set its FY 2025 guidance at 17.000- EPS. On average, equities analysts forecast that Humana will post 16.47 EPS for the current year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a dividend of $0.885 per share. The ex-dividend date is Friday, September 26th. This represents a $3.54 annualized dividend and a dividend yield of 1.2%. Humana’s dividend payout ratio (DPR) is 27.17%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.